Annual CFO
-$11.98 M
+$10.71 M+47.19%
31 December 2023
Summary:
INmune Bio annual cash flow from operations is currently -$11.98 million, with the most recent change of +$10.71 million (+47.19%) on 31 December 2023. During the last 3 years, it has fallen by -$3.04 million (-33.96%). INMB annual CFO is now -3674.42% below its all-time high of -$317.40 thousand, reached on 31 December 2016.INMB Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$6.99 M
+$900.00 K+11.41%
30 September 2024
Summary:
INmune Bio quarterly cash flow from operations is currently -$6.99 million, with the most recent change of +$900.00 thousand (+11.41%) on 30 September 2024. Over the past year, it has dropped by -$2.72 million (-63.84%). INMB quarterly CFO is now -2024.70% below its all-time high of -$328.80 thousand, reached on 31 March 2018.INMB Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$25.75 M
-$2.72 M-11.82%
30 September 2024
Summary:
INmune Bio TTM cash flow from operations is currently -$25.75 million, with the most recent change of -$2.72 million (-11.82%) on 30 September 2024. Over the past year, it has dropped by -$11.47 million (-80.39%). INMB TTM CFO is now -7731.20% below its all-time high of -$328.80 thousand, reached on 31 March 2018.INMB TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
INMB Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +47.2% | -63.8% | -80.4% |
| 3 y3 years | -34.0% | +11.8% | -21.9% |
| 5 y5 years | -481.8% | -259.0% | -375.6% |
INMB Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -34.0% | +58.0% | -512.3% | +28.6% | -114.9% | +20.2% |
| 5 y | 5 years | -481.8% | +58.0% | -1511.9% | +28.6% | -411.7% | +20.2% |
| alltime | all time | -3674.4% | +58.0% | -2024.7% | +28.6% | -7731.2% | +20.2% |
INmune Bio Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$6.99 M(-11.4%) | -$25.75 M(+11.8%) |
| June 2024 | - | -$7.89 M(+5.5%) | -$23.03 M(+25.7%) |
| Mar 2024 | - | -$7.48 M(+119.8%) | -$18.32 M(+52.9%) |
| Dec 2023 | -$11.98 M(-47.2%) | -$3.40 M(-20.2%) | -$11.98 M(-16.1%) |
| Sept 2023 | - | -$4.26 M(+34.3%) | -$14.27 M(+6.7%) |
| June 2023 | - | -$3.17 M(+178.2%) | -$13.38 M(-10.6%) |
| Mar 2023 | - | -$1.14 M(-80.0%) | -$14.96 M(-34.0%) |
| Dec 2022 | -$22.69 M(-20.4%) | -$5.70 M(+69.1%) | -$22.69 M(-15.3%) |
| Sept 2022 | - | -$3.37 M(-29.2%) | -$26.77 M(-14.5%) |
| June 2022 | - | -$4.76 M(-46.3%) | -$31.33 M(-2.9%) |
| Mar 2022 | - | -$8.87 M(-9.4%) | -$32.28 M(+13.2%) |
| Dec 2021 | -$28.50 M | -$9.78 M(+23.4%) | -$28.50 M(+35.0%) |
| Sept 2021 | - | -$7.92 M(+38.8%) | -$21.12 M(+25.0%) |
| June 2021 | - | -$5.71 M(+12.1%) | -$16.89 M(+29.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2021 | - | -$5.09 M(+112.9%) | -$13.00 M(+45.4%) |
| Dec 2020 | -$8.94 M(+66.1%) | -$2.39 M(-35.3%) | -$8.94 M(+28.0%) |
| Sept 2020 | - | -$3.70 M(+103.4%) | -$6.98 M(+33.5%) |
| June 2020 | - | -$1.82 M(+75.7%) | -$5.23 M(+4.0%) |
| Mar 2020 | - | -$1.03 M(+138.8%) | -$5.03 M(-6.6%) |
| Dec 2019 | -$5.38 M(+161.5%) | -$433.40 K(-77.7%) | -$5.38 M(-0.5%) |
| Sept 2019 | - | -$1.95 M(+20.3%) | -$5.41 M(+38.2%) |
| June 2019 | - | -$1.62 M(+16.6%) | -$3.92 M(+25.7%) |
| Mar 2019 | - | -$1.39 M(+200.1%) | -$3.12 M(+51.4%) |
| Dec 2018 | -$2.06 M(+170.3%) | -$462.40 K(+2.8%) | -$2.06 M(+29.0%) |
| Sept 2018 | - | -$449.90 K(-45.0%) | -$1.60 M(+39.2%) |
| June 2018 | - | -$817.80 K(+148.7%) | -$1.15 M(+248.7%) |
| Mar 2018 | - | -$328.80 K | -$328.80 K |
| Dec 2017 | -$761.80 K(+140.0%) | - | - |
| Dec 2016 | -$317.40 K | - | - |
FAQ
- What is INmune Bio annual cash flow from operations?
- What is the all time high annual CFO for INmune Bio?
- What is INmune Bio annual CFO year-on-year change?
- What is INmune Bio quarterly cash flow from operations?
- What is the all time high quarterly CFO for INmune Bio?
- What is INmune Bio quarterly CFO year-on-year change?
- What is INmune Bio TTM cash flow from operations?
- What is the all time high TTM CFO for INmune Bio?
- What is INmune Bio TTM CFO year-on-year change?
What is INmune Bio annual cash flow from operations?
The current annual CFO of INMB is -$11.98 M
What is the all time high annual CFO for INmune Bio?
INmune Bio all-time high annual cash flow from operations is -$317.40 K
What is INmune Bio annual CFO year-on-year change?
Over the past year, INMB annual cash flow from operations has changed by +$10.71 M (+47.19%)
What is INmune Bio quarterly cash flow from operations?
The current quarterly CFO of INMB is -$6.99 M
What is the all time high quarterly CFO for INmune Bio?
INmune Bio all-time high quarterly cash flow from operations is -$328.80 K
What is INmune Bio quarterly CFO year-on-year change?
Over the past year, INMB quarterly cash flow from operations has changed by -$2.72 M (-63.84%)
What is INmune Bio TTM cash flow from operations?
The current TTM CFO of INMB is -$25.75 M
What is the all time high TTM CFO for INmune Bio?
INmune Bio all-time high TTM cash flow from operations is -$328.80 K
What is INmune Bio TTM CFO year-on-year change?
Over the past year, INMB TTM cash flow from operations has changed by -$11.47 M (-80.39%)